7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 5 mg of Stannous Protoporphyrin and They will be exposed to sunlight one hours every day for 14 days

7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 7 mg of Stannous Protoporphyrin and They will be exposed to sunlight two hours every day for 14 days

7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 9 mg of Stannous Protoporphyrin and They will be exposed to sunlight three hours every day for 14 days

7 subjects with COVID-19 infection and Serum ferritin < 500 ng/ml will receive a single dose of 5 mg of sulfonatoporphyrin(TPPS), and They will be exposed to sunlight two hours every day for 14 days

COVID-19

SnPP Protoporphyrin plus Sunlight exposure

SnPP Protoporphyrin and Sunlight exposure

Sulfonatoporphyrin(TPPS) plus Sunlight exposure.

placebo

Kafr El-sheikh University

Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients

Efficacy of Based MRI Contrast Media Against Covid-19

Proportion of lung injury score decreased or increased after treatment

Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon

less than 250 ng/mL, or less than 0.4 mcg/mL of blood sample

Mahmoud Ramadan mohamed Elkazzaz

Principal Investigator

Kafrelsheikh University

Patients and method :
This study will performed on 56 participants tested positive for the presence of COVID-19 RNA by RT-PCR kit for RNA detection and 56 participants will divided into 8 equal groups

Patients
This study will performed on 56 participants tested positive for the presence of COVID-19 RNA by RT-PCR kit for RNA detection and 56 participants will divided into 8 equal groups

Patients with a Tyrosinemia type 1 or high-grade suspi-cion for Tyrosinemia type 1

For the development of the new biomarkers using the technique of Mass-spectrometry, a blood sample of maximal 7,5 ml blood will be taken from the patient via using a dry blood spot filter card. To proof the correct diagnosis a Tyrosinemia type 1, in those patients where up to the enrollment in the study no genetic testing has been done, sequencing of a Tyrosinemia type 1 will be done. The analyses will be done at: Centogene AG Am Strande 7 18055 Rostock Germany

Tyrosinosis

Hepatorenal Tyrosinemia

Fumarylacetoacetase Deficiency

Fah Deficiency

Metabolic Disorders

Centogene is one of the leading laboratories focusing on genetic testing for rare hereditary disorders. We now offer more than 2200 routine genetic and biochemical tests.

Centogene AG

NIRMAN Navi Mumbai Institute of Research In Mental And Neurological Handicap/Pediatric Geneticist

Lady Ridgeway Hospital for Children

Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)

BioTyrosin - Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 - An International, Multicenter, Epidemiological Protocol

Next-Generation Sequencing (NGS) of the FAH gene will be performed. The mutation will be confirmed by Sanger sequencing.

The quantitative determination of small molecules (molecular weight 150-700 kD, given as ng/μl) within a dried blood spot sample will be validated via liquid chromatography multiple reaction-monitoring mass spectrometry (LC/MRM-MS) and compared with a merged control cohort. The statistically best validated molecule will be considered as a disease specific biomarker.

Centogene AG Rostock

1. Anesthesia-sedation KETOFOL 1-1: Two milligrams per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:1 (one milligram of ketamine per one milligram of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedures previously defined in the inclusion criteria.

2. Anesthesia-sedation KETOFOL 1-2: One milligram per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:2 (one milligram of ketamine per two milligrams of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedure previously defined in the inclusion criteria.

Anesthesia; Reaction

After randomization to the study group, the patients were given:
Procedures < 10 minutes
Ketamine-Propofol Combination KETOFOL 1:1
Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)
Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)
Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)
Ketamine-Propofol Combination KETOFOL 1:2
Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)
Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)
Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)
Procedures > 10 minutes
In addition to the initial bolus, an infusion was started:
KETOFOL 1:1
20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN
KETOFOL 1:2
20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN
Speed infusion:
0,03cc/kg/min

Ketamina-Propofol Combination

Efficacy of Ketamine-Propofol for Short Surgical Procedures

EFFICACY OF KETAMINE-PROPOFOL COMBINATION FOR SHORT SURGICAL PROCEDURES

Sedation / analgesia was considered successful if the procedure was completed without the need for other anesthetic drugs are different from the protocol, and yes no adverse effects to oblige the completion of the procedure. Apnea was defined as cessation of breathing for at least 20 seconds. Hypotension was defined as 20% decrease in mean arterial pressure. Bradycardia was defined as a pulse of less than two standard deviations below normal values defined by the American Heart Association (AHA_ for its acronym in Ingles_). Hypoxia was defined by an oxygen saturation of less than 90%.

Dr. Ricardo Poveda Jaramillo

Anesthesiology Resident

Universidad de Cartagena

Acute Myocardial Infarction

1-3 x heme arginate infusion, in 30 minutes iv. Heme arginate is dissolved in 250 ml NACl.

Heme arginate

Official site of the University Medical Centre Groningen

porphyrias/febre

Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients

Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)

Efficacy of Ketamine-Propofol for Short Surgical Procedures

Does Heme Oxygenase-1 Induction Ameliorate Cardiac Injury After Myocardial Infarction?

O mais completo banco de dados de ervas medicinais apoiado pela ciência